Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics Inc (NQ: APRE )

2.600 +0.060 (+2.36%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aprea Therapeutics Inc

< Previous 1 2 3 4 5 Next >
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics: Q4 Earnings Insights
Via Benzinga
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
From Aprea Therapeutics
Via GlobeNewswire
APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024
APRE stock results show that Aprea Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape 
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
From Aprea Therapeutics
Via GlobeNewswire
APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024
APRE stock results show that Aprea Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
New role enhances company’s strong leadership team and solidifies commitment to ongoing clinical innovation 
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
From Aprea Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023
APRE stock results show that Aprea Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
From Aprea Therapeutics
Via GlobeNewswire
Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?
FDA clearance for Aprea Therapeutics' APR-1051 IND application, a promising WEE1 kinase inhibitor. Phase 1 trial initiation in 2024, focusing on Cyclin E cancers. $34 million private placement to fund... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
Four Poster Presentations, Including Posters on ATRN-119 (novel macrocyclic ATR inhibitor) and APR-1051 (next generation WEE1 kinase inhibitor) 
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
From Aprea Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.